UNSPSC 51151600: Cholinergic blocking agents

This classification denotes drugs that inhibit cholinesterases. the neurotransmitter acetylcholine is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. when cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system.

UNSPSC 51151600 Cholinergic blocking agents is a Class code that captures state and local procurement of pharmaceutical products used in emergency response and public health interventions, specifically naloxone and related drug-response systems. State and local issuing bodies—primarily county health departments and state health and human services agencies—solicit these products to support opioid overdose response, community health initiatives, and pharmacy benefit programs. The work involves supply and delivery of finished pharmaceutical products with quarterly or ongoing fulfillment schedules, e-procurement portal submission, and compliance with drug-free workplace certification and E-Verify requirements. Vendors must handle logistics including shipping and delivery costs, maintain appropriate insurance coverages, and operate under fixed-fee or negotiated pricing structures. When FEMA funding is involved, contractors face additional compliance obligations under federal environmental and regulatory statutes.

Recent activity shows two distinct procurement approaches: Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs and alternative contracting models outside traditional pharmacy benefit manager and group purchasing organization channels. Florida and Texas represent the geographic spread evident in recent activity. The code shows limited recent volume—two opportunities across two states in the source period—suggesting either narrow issuing-body demand, sparse posting of state and local pharmaceutical solicitations in aggregated databases, or misalignment between the code classification and actual procurement patterns for naloxone and related products in state and local health systems.